A meta-analysis of controlled clinical trials comparing postoperative adjuvant chemoradiotherapy with adjuvant chemotherapy in patients with gastric cancer
GUO Qi*,HUANG Wei-xian, CUI Xi-xi, ZHANG Li-yuan,TIAN Ye.*
Second Hospital Affiliated to Soochow University, Suzhou 215004, China
Abstract：Objective To compare postoperative adjuvant chemoradiotherapy with adjuvant chemotherapy in patients with gastric cancer by a meta-analysis. Methods PubMed, EMbase, Cochrane Library, Wanfang, CNKI, VIP, and CBM databases were searched to identify the controlled clinical trials of postoperative adjuvant chemoradiotherapy versus adjuvant chemotherapy for gastric cancer. The obtained data were analyzed using RevMan 5.2.5 and Stata 12.0. The difference between two groups was estimated by calculating the odds ratio (OR) with 95% confidence interval (CI). Results A total of 12 controlled clinical trials involving 1674 gastric cancer patients, which were selected according to inclusion and exclusion criteria, were included in this meta-analysis. The meta-analysis showed that the 3-and 5-year survival rates were significantly higher in the adjuvant chemoradiotherapy group than in the adjuvant chemotherapy group (OR=2.96, 95%CI=1.75—5.03, P=0.000;OR=1.45, 95%CI=1.06—1.99, P=0.020);the local recurrence rate was significantly lower in the adjuvant chemoradiotherapy group than in the adjuvant chemotherapy group (OR=0.50, 95%CI=0.34—0.72, P=0.000);there was no significant difference in distant metastasis rate between the two groups (OR=0.79, 95%CI=0.58—1.07, P=0.130). Conclusions The meta-analysis of existing study results shows that compared with adjuvant chemotherapy alone, adjuvant chemoradiotherapy is a relatively safe and effective postoperative treatment for gastric cancer.
GUO Qi,HUANG Wei-xian,CUI Xi-xi et al. A meta-analysis of controlled clinical trials comparing postoperative adjuvant chemoradiotherapy with adjuvant chemotherapy in patients with gastric cancer[J]. Chinese Journal of Radiation Oncology, 2013, 22(6): 433-436.
[1] Taketa T, Sudo K, Wadhawa R, et al. Adjuvant therapy in gastric cancer:what is the optimal approach? Curr Oncol Rep,2013,15:146-151. [2] Stessin AM, Sherr DL. Demographic disparities in patterns of care and survival outcomes for patients with resected gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev,2011,20:223-233. [3] Dassen AE, Dikken JL, van de Velde CJ, et al. Changes in treatment patterns and their influence on long-term survival in patients with stage Ⅰ－Ⅲ gastric cancer in the Netherlands. Int J Cancer,2013,133:1859-1866. [4] Zhang X, Li N, Wei W, et al. Clinical management of gastric cancer:results of a multicentre survey. BMC Cancer,2011,11:369. [5] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med,2002,21:1539-1558. [6] DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials:an update. Contemp Clin Trials,2007,28:105-114. [7] Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA,2006,295:676-680. [8] Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol,2012,104:361-366. [9] Yu C, Yu R, Zhu W, et al. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol,2012,138:255-259. [10] Lee J, Kim S, Park SH, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial. J Clin Oncol,2012,30:268-273. [11] Kim TH, Park SR, Ryu KW, et al. Phase 3 Trial of postoperative chemotherapy alone versus chemoradiation therapy in stage Ⅲ－Ⅳ gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys,2012,84:585-592. [12] 杨治花,折虹,闫钢,等.局部进展期胃癌根治术后同期放化疗与单纯化疗的临床比较.中华放射肿瘤学杂志,2012,21:252-254. [13] 徐海平.局部进展期胃癌术后同步放化疗的临床分析.中华肿瘤防治杂志,2012,19:704-706. [14] Kwon HC, Kim MC, Kim KH, et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol,2010,6:278-285. [15] Bamias A, Karina M, Papakostas P, et al. A randomized phase Ⅲ study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol,2010,65:1009-1021. [16] 胡广原,魏瑶,梅齐,等.进展期胃癌术后同步放化疗 32 例的回顾分析.中国临床医学,2009,16:553-555. [17] 李华,胡艳文,田大龙,等.中晚期胃癌根治术后同步放化疗临床观察.山东医药,2008,48:47-48. [18] 瞿广桥,熊斌.进展期胃癌术后同步放化疗的临床观察.实用癌症杂志,2006,21:390-391. [19] 刘阳晨,周绍兵,高飞.进展期胃癌术后同步放化疗的临床研究.现代肿瘤医学,2004,12:4565-4573. [20] Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116:a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol,2012,30:2327-2333. [21] Jácome AA, Wohnrath DR, Neto CS, et al. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer,2013,16:233-238. [22] CostaWL Jr, Coimbra FJ, Fogaroli RC, et al. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer:the role of n-ratio in patient selection. results of a single cancer center. Radiat Oncol,2012,7:169. [23] 王鑫,金晶,李晔雄,等.局部晚期胃癌根治术后复发部位分析及对术后放疗意义的探讨.中华放射肿瘤学杂志,2011,20:133-137. [24] Boda-Heggemann J, Hofheinz RD, Weiss C, et al. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastriccancer. Int J Radiat Oncol Biol Phys,2009,75:1187-1195. [25] Strauss J, Hershman DL, Buono D, et al. Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impacton survival. Int J Radiat Oncol BiolPhys,2010,76:1404-1412. [26] 秦玉娥,周福祥,戴静,等.进展期胃癌根治术后放化疗与单纯化疗预后分析.中华放射肿瘤学杂志,2013,22:263-265. [27] Ohri N, Garg MK, Aparo S, et al. Who benefits from adjuvant radiation therapy for gastric cancer?Ameta-analysis. Int J Radiat Oncol Biol Phys,2013,86:330-335.
2013, Vol. 22 
